Jiangsu Kangyuan Pharmaceutical Co., Ltd. Announcement on the Appointment of Vice General Manager

Stock Short Name: Kangyuan Pharmaceutical Stock Code: 600557 Announcement No.: 2026-005

Announcement of Jiangsu Kangyuan Pharmaceutical Co., Ltd. on the Appointment of a Deputy General Manager

The board of directors of the Company and all directors hereby guarantee that there are no false records, misleading statements, or material omissions in the contents of this announcement, and assume legal responsibility for the truthfulness, accuracy, and completeness of its contents.

The notice of the 24th extraordinary meeting of the eighth session of the board of directors of Jiangsu Kangyuan Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) was issued on March 28, 2026 by written documents, telephone, and electronic mail. The meeting was held on March 30, 2026 at the Company’s conference room in a combination of in-person and communications-based means. There were 11 directors required to attend the meeting, and 11 directors actually attended. The convening of this meeting complies with laws and regulations including the “Company Law,” as well as the provisions of the “Company Articles of Association.” The meeting was chaired by Mr. Wang Zhenzhong, the vice chairman of the board. By means of show-of-hands and communications-based voting, the relevant resolution on “Appointment of a Deputy General Manager” was unanimously approved. The specific details are hereby announced as follows:

To further strengthen the Company’s management leadership team and meet the Company’s development needs, in accordance with the relevant provisions of the “Company Law” and the “Company Articles of Association,” and upon nomination by the Company’s general manager and approval by the Company’s special meeting of independent directors, the board of directors has appointed Mr. Xiao Lihao (see the resume attached) as the Company’s deputy general manager. His term shall commence from the date on which the board of directors approves the appointment and shall end on the date on which the term of the eighth session of the board of directors expires.

As of now, Mr. Xiao Lihao directly holds 40,000 shares of the Company, accounting for 0.0071% of the Company’s total share capital. He and the Company’s actual controller, Mr. Xiao Wei, are parties acting in concert. Other than that, there is no relationship between him and the Company’s directors, senior management, or shareholders holding 5% or more of the Company’s shares. There is no circumstance in which he is prohibited from serving as a senior management officer of the Company as stipulated in the “Company Law” and the “Company Articles of Association.” He has not been subject to administrative penalties imposed by the China Securities Regulatory Commission or sanctions by an exchange. There are no other circumstances identified by the Shanghai Stock Exchange as making him unsuitable to serve as a senior management officer of a listed company. After inquiries, he is not a person subject to enforcement for dishonesty. He meets the requirements for the appointment qualifications of senior management officers of the Company under relevant laws, administrative regulations, and normative documents, including the “Company Law” and “Shanghai Stock Exchange Listing Rules for Self-Regulatory Guidance No. 1—Regulation of Operation,” among others.

This announcement is hereby issued.

Board of Directors of Jiangsu Kangyuan Pharmaceutical Co., Ltd.

March 30, 2026

Mr. Xiao Lihao: Born in August 1994. He holds a doctoral degree, is a member of the Communist Party of China, has Chinese nationality, and has no permanent right of residence abroad. From September 2020 to June 2024, he served as Secretary of the Youth League Committee, Assistant to the Chairman, and Chairman of a subsidiary of Kangyuan Group of Jiangsu Kangyuan Group Co., Ltd., among other positions. From June 2024 to the present, he has served as Chairman of Jiangsu Kangyuan Yangguang Pharmaceutical Co., Ltd. Starting in December 2025, he has served as a director of the board of directors of the eighth session of the Company.

A wealth of information and precise interpretation—available on Sina Finance APP